Troy Hamilton
Chief Executive Officer at Ellodi Pharmaceuticals
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Todd Sisitsky | M | 52 |
Ellodi Pharmaceuticals
 Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | - |
| John Schilling | M | - |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | - |
| Katherine Wood | F | 38 |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | 4 years |
| Debra Silberg | M | - |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | 1 years |
| James Nezamis | M | - |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | - |
| Martin Waga | M | - |
Ellodi Pharmaceuticals
Ellodi Pharmaceuticals BiotechnologyHealth Technology Ellodi Pharmaceuticals engages in the provision of pharmaceutical services. It is dedicated to the clinical development of APT-1011, a novel therapy in Phase 3 development for the treatment of Eosinophilic Esophagitis (EoE) spun-out of Adare Pharmaceuticals (Adare). The company is headquartered in the United States. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gary Jacob | M | 77 | - | |
| Kunwar Shailubhai | M | 67 | 16 years | |
| Melvin Spigelman | M | 75 | 11 years | |
| Bernard Denoyer | M | 77 | 9 years | |
| John Brancaccio | M | 76 | 11 years | |
| Timothy Sean Callahan | M | 53 | 4 years | |
| Thomas H. Adams | M | 81 | 10 years | |
| Alan F. Joslyn | M | 65 | 10 years | |
| Joseph J. Farnan | M | 78 | - | |
| Richard Daly | M | 62 | 3 years | |
| Chhaya Shah | F | 60 | 3 years | |
| Vaseem Palejwala | M | - | 5 years | |
| Marianne Jackson | F | - | - | |
| Pam Cebulski | F | - | - | |
| Patrick Griffin | M | 68 | 5 years | |
| Dan Dunham | M | - | - | |
| Marino Garcia | M | 57 | 4 years | |
| Gary Gemignani | M | 58 | 2 years | |
| Gary Sender | M | 62 | 1 years | |
| Gem Hopkins | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 26 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Troy Hamilton
- Personal Network
